PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that its Chief Financial Officer Evan Myrianthopoulos will present a company overview highlighting recent developments at the BIO Investor Forum.
The presentation will take place on Thursday, October 29, 2009 at 1:00 PM PDT at The Palace Hotel in San Francisco, CA.
The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company's investor page at http://www.soligenix.com/invest_sec.shtml. The replay will be available 24 hours after the live presentation and will be accessible for 30 days.
About the BIO Investor Forum
The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors and research analysts, as well as business development executives from leading global pharmaceutical and mature biotechnology companies.
About Soligenix, Inc.
Soligenix, Inc. (Soligenix), formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVH
|SOURCE Soligenix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved